Neuroprotective effects of an engineered commensal bacterium in the 1 ‐methyl‐4‐phenyl‐1, 2, 3, 6‐tetrahydropyridine Parkinson disease mouse model via producing glucagon‐like peptide‐1

In this study, we developed a MG1363 ‐pMG36e‐GLP‐1 strain to continuously express GLP‐1, and found this strain had effectively alleviated the decrease in motor function and reduced the α‐Syn expression in mice brain caused by MPTP via increasing tyrosine hydroxylase (TH)‐positive neurons, suppressing microglia andastrocyte s activation, down‐regulating inflammatory factors expression, and regulating gut microbiota composition. Therefore, this strain can be served as a safe and effective agent for PD treatment. AbstractWhile glucagon ‐like peptide‐1 (GLP‐1) was reported to have a positive impact on Parkinson disease, it is extremely short half‐life greatly hindered its clinical use. In this study, the mouse strain MG1363‐pMG36e‐GLP‐1 was engineered to continuously express GLP‐1 to treat Parkinson disease in a 1‐ methyl‐4‐phenyl‐1, 2, 3, 6‐tetrahydropyridine (MPTP)‐treated Parkinson disease model. In our study, oral supplementation with MG1363‐pMG36e‐GLP‐1 significantly (p <  0.05) reduced MPTP‐induced locomotor impairments, increased tyrosine hydroxylase‐positive neurons, suppressed microglia and astrocyte activation, and down‐regulated expression of several inflammation‐related molecules. In addition, MG1363‐pMG36e‐GLP‐1 significantly (p <  0.01) reduced intestinal pathogenEnterobacteriaceae and markedly enhanced the number of probioticLactobacillus andAkkermansia. These data suggest that MG1363 ‐pMG36...
Source: Journal of Neurochemistry - Category: Neuroscience Authors: Tags: Original Article Source Type: research